Safety and Immunogenicity of Heterologous Prime-boost With the Candidate Malaria Vaccines AdCh63 ME-TRAP and MVA ME-TRAP in Healthy Adults in a Malaria Endemic Area.

Trial Profile

Safety and Immunogenicity of Heterologous Prime-boost With the Candidate Malaria Vaccines AdCh63 ME-TRAP and MVA ME-TRAP in Healthy Adults in a Malaria Endemic Area.

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Oct 2012

At a glance

  • Drugs ME-TRAP malaria DNA vaccine Okairos (Primary) ; ME-TRAP malaria DNA vaccine Okairos (Primary)
  • Indications Malaria
  • Focus Adverse reactions
  • Most Recent Events

    • 02 Oct 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 15 Jun 2012 Actual end date May 2011 added as reported by ClinicalTrials.gov.
    • 15 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top